Figure 2.

DNA repair capacity and GSH concentration in glioma cell lines. (a) HCR assay with a luciferase plasmid treated with increasing doses of cisplatin. (b) Quantification of γH2AX-positive cells upon cisplatin treatment, as detected by flow cytometry. (c) Quantification of the basal intracellular GSH concentration in the four glioma cell lines. (d) Quantification of the intracellular GSH concentration after BSO or NAC incubation. (e) Cellular viability, as determined by the XTT assay, in cells treated with BSO or NAC combined with cisplatin. (f) The percentage of apoptotic cells, as measured by the sub-G1 population, after treatment with cisplatin in combination with BSO or NAC. Values are mean±S.E.M. of three independent experiments, *P<0.05, **P<0.01 and ***P<0.001